First hemophilia A patient dosed in trial of BBM-H803 in China
The first patient has been dosed in China in a registrational clinical trial of BBM-H803, a one-time investigational gene therapy…
Articles by Margarida Maia, PhD
SerpinPC safe, reduces bleeds for almost 3 years: Study
SerpinPC, an experimental treatment being developed by Centessa Therapeutics, continues to be safe when used for up to nearly…
Gene therapy for hemophilia A reduces bleeding in clinical trial
GS1191, a gene therapy in the pipeline of Gritgen Therapeutics, increased factor VIII (FVIII) activity in the blood of…
Hemophilia mortality rates in US higher among Black males: Study
People with hemophilia are living longer, but Black males still are more likely to die from the disease, and…
Switching to extended half-life products may help reduce bleeds
Switching from on-demand treatment to regular preventive therapy with extended half-life products may mean fewer bleeds, healthier joints, and better…
More bleeds can negatively affect life, work for men with Hem A
More bleeding episodes may mean a lower quality of life and less productivity at work for men with hemophilia…
Gene therapy for hemophilia B under review in US, Europe
Regulatory agencies in the U.S. and Europe are reviewing applications seeking the approval of fidanacogene elaparvovec, an experimental one-time…
$1.5M grant will fund research into TIPS to aid hemophilia A treatment
A researcher at the University at Buffalo has won a three-year grant worth $1.5 million to develop a way to…
Study finds care, treatment limited for hemophilia patients in Thailand
Hemophilia treatments in Thailand are limited due to a lack of budgetary resources, the high cost of medications, and…
Hemophilia A undertreated in female patients, carriers: US study
Female hemophilia AÂ patients and carriers have more frequent bleeding than males, yet a much smaller proportion receive…